Ophthalmology turned a corner with the arrival of corticosteroids, and Fluorometholone’s story weaves through that progress. Back in the mid-20th century, as doctors kept running into the limits of existing corticosteroids for eye inflammation, pharmaceutical chemists pushed to improve the structure. Drawing on early advances with hydrocortisone, researchers played with molecular tweaks, aiming for something kinder to the eye and less risky for intraocular pressure. By the 1960s, after lots of trial and error, Fluorometholone hit the market as a topical agent. Its launch was a response to the need for corticosteroids that didn’t spike eye pressure as often. Before this discovery, older steroids often left patients with tough choices—tolerate swelling or risk glaucoma. Fluorometholone carved out a spot with a lower rate of those side effects, earning quick acceptance among specialists.
People with eye allergies, uveitis, or post-operative inflammation don’t want relief that brings a stack of new problems. Fluorometholone addresses that everyday worry. It sits in products like drops and ointments, working by tamping down immune responses on the eye’s surface. Unlike more potent cousins, it provides anti-inflammatory benefits while limiting pressure spikes that can permanently reduce vision. Patients and clinicians look for that balance: enough punch to handle redness, swelling, and discomfort, but with a lower chance of long-term trouble. Bottled as an alcohol or acetate, the product travels through pharmacies and clinics as a familiar answer to common eye irritation and healing needs. Over half a century later, its name still shows up because people trust it for these reasons.
Understanding what sets Fluorometholone apart starts with its core structure. This medicine belongs to the glucocorticoid family. Chemists recognize its backbone as a steroid, with a fluorine atom at the ninth position, which ramps up its anti-inflammatory character. The compound shows up as a white to off-white crystalline powder that dissolves best in alcohols and a few organic solvents but hardly moves in water. Its formula, C22H28F O4, combines that visible fluorine tweak with methyl groups, pointing to how even tiny changes can impact biology. Melting around 289°C, it resists breakdown, making it stable enough to handle the supply chain and pharmacy shelf. Chemists often refer to its logP value—the marker for how fat-loving the molecule is—demonstrating Fluorometholone’s preference for tissues instead of water, something that influences how it moves through the eye’s layers.
Pharmaceutical makers lean on tight standards with corticosteroids. Fluorometholone drops, usually at 0.1%, require fine-tuned particle sizes, sterility, and pH checked between 5.0 and 7.5 to match what’s comfortable in the human eye. The U.S. Pharmacopeia and European Pharmacopoeia give detailed monographs, spelling out how pure, how strong, and how clean every batch needs to be. Labels mark active concentration, expiration dates, and storage instructions clearly, warning users to avoid contamination and noting possible risks if overused. Country regulations may vary, but documentation always covers dosages, contraindications (like existing eye infections), adverse effects, and specific handling measures for pharmacy staff or home users. Packaging often includes protective sleeves or single-use vials, aiming to reduce the chances of bacteria getting inside after the seal breaks.
Manufacturing Fluorometholone draws on a thorough understanding of organic synthesis. The journey starts with a suitable steroid backbone, usually built from pregnenolone or similar starting blocks. Chemists introduce a fluorine atom using selective halogenation, all while watching out for unwanted byproducts. Methylation steps shape select spots in the molecule, using either methyl iodide or other methyl group donors. Later, the team adds or removes oxygen atoms at precise points in the carbon skeleton. Each phase requires exact control over temperature, solvents, and time, sometimes stretching across multiple days of work. When the target compound forms, the batch gets purified, either through recrystallization or chromatographic techniques. After the active pharmaceutical ingredient passes purity checks, it’s weighed, packed, and eventually blended into eye drop solutions under sterile conditions. The full route is labor-intensive, and no shortcuts survive regulatory scrutiny.
Tinkering with Fluorometholone’s chemical skeleton over the years has offered both academic interest and hope for better treatments. The fluorine substitution at C9 is the hallmark modification—this change boosts anti-inflammatory power and stability, compared to its parent compounds. Chemists have tried to modify side chains or esterify the molecule, which can shift how quickly the drug works or how long it lasts in tissues. Acetate derivatives, for example, slow down release in the eye, helping some patients avoid frequent dosing. Chemical work often bumps up against a stubborn reality: not every molecular tweak improves things in people. Sometimes, changes mean more side effects or trouble getting into the cornea. Yet, each effort broadens understanding about how small shifts can swing the balance between help and harm.
Pharmacies may call Fluorometholone by a few different names. The most straightforward: “FML,” which pops up in eye drop form. You’ll also see brand names like Flarex and FML Forte for more concentrated or specialized formulations. International regulators use the same active ingredient, “fluorométholone” in French and other minor spelling variations, but the molecule underneath remains unchanged. Chemical references might list alternatives like 9α-Fluoro-11β,17α-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione, though most clinicians avoid these technical mouthfuls unless the conversation turns especially scientific.
Using corticosteroids on the eyes calls for serious attention to patient history and ongoing monitoring. Too much, too long, and doctors start seeing pressure jumps or even cataracts. For Fluorometholone, the risk is lower than with others—dexamethasone in particular—but the safety margin never stretches far. Guidelines recommend tapering off, not stopping cold, once the acute symptoms settle down. Bottles need to be sterile at point of use, and the tip must not touch skin or surfaces. Storage at room temperatures plus awareness of expiration dates protect against lost potency or contamination. Dispensing pharmacists must keep tight records, follow up with patients about side effects, and offer detailed instructions for home users, since improper technique with eye drops isn’t rare. Side effects usually stay local—redness, stinging—but prompt reporting helps catch the rare, severe complications that can threaten vision.
Doctors turn to Fluorometholone for a narrow set of eye problems: allergy-driven swelling, post-surgical healing, superficial punctate keratitis, and some cases of chronic inflammation like uveitis. It rests in the toolkit as a less aggressive, targeted agent—especially for people prone to increased eye pressure. Its so-called “soft steroid” profile means fewer worries about major systemic absorption, which parents appreciate if their children need short itchy-eye stints. It can’t touch deeper inflammation or infections, so its role stays focused on surface or near-surface issues. Real-world clinic visits reflect this: docs prescribe it for an itch or flare-up, monitor the eye’s response closely, then look for reasons to taper rather than extend use. Patient compliance hinges on clear explanations and scheduled follow-ups, not merely a prescription drop in the box.
Researchers keep testing tweaks to Fluorometholone, chasing either improved delivery or novel applications. Some groups combine it with antibiotics or lubricants in a bid to create combo-cocktails for post-surgical patients. Others test nanoemulsion or liposomal forms, aiming for steadier dosing or better comfort. While some lab results look promising, real-world improvements have to prove themselves in randomized trials—past lessons from the field remind us that lab gains don’t always translate to actual patient outcomes. Grants and funding focus on reducing the risk of steroid-induced glaucoma, making it crucial to have long-term studies with diverse patient groups. Even with the search for innovation, companies stick with established safety data and clinical experience, which helps avoid unexpected disasters that emerged with earlier classes of eye drugs.
Animal and human studies have painted a clear outline of Fluorometholone’s safety net. Acute exposure rarely causes trouble apart from mild stinging, but chronic or high-dose use stands out as the primary risk. Toxicology groups track the presence of cataracts, corneal thinning, and pressure elevations. Experiments point to a strong safety track record compared to older and more potent steroids, though heavy use still brings risk. Systemic effects remain scarce due to limited absorption in the eye, but researchers look hard for subtle hormonal impacts, especially in babies or those using large volumes. Long-term animal studies back up low mutagenic or carcinogenic potential, supporting its place among preferred eye steroids worldwide.
Future work with Fluorometholone plays out on several fronts. Drug makers look for better delivery—improved penetration, fewer doses, and even gentler formulations that address preservative sensitivities. Markets in Asia and Africa signal unmet demand for safe, cheap anti-inflammatory agents, linking this compound’s future to both innovation and access. Medical researchers consider mixing it with biologics or device delivery (like punctal plugs) as possible next steps. Policy and safety watchdogs expect reporting systems and follow-up studies before any change in clinical use scales up. As eye disease remains a global issue—especially with the upswing in allergic diseases and aging populations—Fluorometholone will likely keep helping people see comfortably, guided by a stronger research base and a healthy respect for long-term safety.
Fluorometholone isn’t a name you hear often at the pharmacy counter unless you’ve been dealing with eye problems. It’s a corticosteroid drop specifically for the eyes. Doctors reach for this medication when the eye feels irritated and inflamed — think red, swollen, or itchy. The point isn’t just to settle symptoms, but to help heal the deeper problem in the tissue, so everyday life gets a bit easier and clearer for folks struggling with eye trouble.
Living with irritated eyes brings more than discomfort. Untreated inflammation affects work, sleep, reading, and even driving. Having an effective medicine like fluorometholone means people can get back to their routines without the constant aggravation. Most commonly, eye doctors prescribe this drop after eye surgery, during flares of allergic conjunctivitis, or with inflammatory issues like uveitis. In these moments, using this drop can keep more serious complications from taking root.
Here’s the thing about eye issues – they can come out of nowhere. A few years ago, red, scratchy eyes ruined several weeks for me. The over-the-counter antihistamine drops didn’t touch it. The irritation built up fast, and workdays at the computer turned miserable. My eye doctor prescribed fluorometholone. Within days, the burning started to fade and the tint of red in my eyes eased back to normal. I could work late at my screen and fall asleep without gritty discomfort. The simple ability to go through my routine felt like a return to normal life.
Fluorometholone works best when real inflammation drives the problem. It’s not a go-to just for every sting or itch. Used without cause, steroids can cause more harm than good, raising the pressure inside the eye or making infections worse. This is the main reason the prescription matters: the doctor needs to check that the cause isn’t something risky like an infection. I remember being warned to watch for side effects and to come back if vision changed.
Eye steroids carry power but need careful respect. Studies show that even a short course can help reduce inflammation, yet there’s always concern about the risk of glaucoma or cataract with repeat long-term use. It helps if the doctor checks your eye pressure, especially for those who have family risk for glaucoma.
Not everyone responds the same way to these drops. Allergies, pre-existing eye disease, or even just genetics can change the risk. Researchers continue looking into options that tweak the formula so fewer people face side effects. Some advances even mix in antibiotics, which covers the infections that sometimes ride along with inflammation.
Using fluorometholone takes more than just squeezing a few drops in. Doctors teach the right way to apply it, space it out, and keep hands clean. Patients do better when they ask questions – like how long this is safe, and what early warnings (like blurry vision or pain) should prompt a call to the clinic. Good vision underpins independence, so getting ahead of inflammation matters. If you’ve ever relied on your eyes for work or play, having this treatment as a backup brings real peace of mind.
Fluorometholone, a corticosteroid often prescribed as an eye drop, helps people battle inflammation after surgery or in ongoing eye irritation. Many folks breathe a sigh of relief after a few doses, since the redness fades and the pain calms down. For those with sensitive eyes, just getting through the workday without constant scratching can feel like a small miracle. What often gets overlooked is the other side of the story—side effects that sneak up, especially after long stretches of use.
Some people start noticing a stinging feeling right after the drops hit the eye. That raw, watery sting catches many off guard, especially if you’re hoping for relief. Redness can actually spike for a bit, leaving folks wondering if they’ve done more harm than good. Occasionally, the eyelids puff up or develop itching that makes mornings rough. One of my neighbors mentioned trouble keeping her eyes open at work because of the heavy sensation these side effects brought.
Extended use brings more than surface-level aches. Eye pressure starts to climb in some patients, especially those who already deal with glaucoma risk. Doctors check for this jump in pressure closely, as unchecked buildup can damage the optic nerve and steal away vision, sometimes quietly. Reports link steroid use to thinning of the cornea or lens opacities—cataracts don’t just show up with age. For people who already struggle with dry eye or weak corneas, risks stack up quickly.
Corticosteroids work by telling the immune system to hit the brakes. That’s perfect for inflammation, but that quiet immune system can roll out the red carpet for bacteria, viruses or fungi. Pink eye, cold sores on the eyelids, and other unexpected eye infections have an easier time flaring up. Since steroids often mask the swelling and redness that tip off infection, sometimes people don’t realize there’s a bigger problem until things spiral.
Fluorometholone comes with a warning label for good reason. Children, elderly folks, and immunocompromised patients face higher risks. Over time, eyes treated with steroids can thin out, scar or form ulcers, especially if a viral infection is simmering unnoticed. If cataracts develop, only surgical intervention can fix the problem. The financial and personal costs of extra procedures or lost vision go far beyond the pharmacy counter.
Regular follow-ups with an eye doctor make a huge difference. Keeping those appointments has helped friends of mine catch pressure spikes early and dodge nerve damage. It’s often safer to use the lowest effective dose for the shortest time possible. For dry or sensitive eyes, some ophthalmologists recommend using lubricating drops in tandem, or reducing exposure with extra caution. People should always flag new vision changes or pain, even if they seem small at first. Pharmacists and doctors stay ready to help with questions, so don’t let worries about side effects go unshared. Real stories shared among family, friends, or through trustworthy health networks can encourage others to speak up and avoid silent harm.
Medicine brings relief for many, but it also asks us to pay attention to new signals from our bodies. Learning how to balance help and harm builds trust and saves sight—especially for those who rely on clear vision for work, parenting, or simple day-to-day life. It pays to stay curious and share observations, since someone else’s story can make all the difference in catching an early warning sign.
Eye inflammation and allergies often trigger redness, swelling, or itching that disrupt daily routines. Doctors reach for steroid eye drops like fluorometholone to bring that inflammation down so eyes get a fair shot at healing. The medication tackles swelling inside the eye by calming the body’s response, and helps people see and feel better faster.
Doctors prescribe fluorometholone with caution because steroids, even in the eye, come with risks. My time in pharmacy practice taught me how missing doses, sharing bottles, or overusing drops cause problems no patient expects. Prescribers typically start with two to four times a day, but the pattern depends on how irritated the eye looks, or how symptoms change.
Using these drops only as directed is not just a phrase doctors toss around. Steroids can thin the delicate eye tissues, and letting drops drip down the face or rubbing afterwards increases risk. After shaking the bottle, tilt the head back, look up, and create a small pocket by gently pulling the lower eyelid down. Squeeze just one drop and close your eye for a few moments—wiping away the excess around your eyelids keeps it from entering your bloodstream through the skin.
Some folks forget that clean hands matter as much as clean medicine. Touching the tip of the bottle to your eye or lashes risks putting bacteria right into the drops and, eventually, the eye. In pharmacy school, we routinely reminded people to wash hands and keep the tip of the dropper away from surfaces. Even the smallest contamination sometimes leads to infections, especially when steroids lower the eye’s natural defenses.
No medication is free of side effects. People using steroid drops longer than two weeks build up a real risk for increased eye pressure, which can pave a direct path to glaucoma. Steroid use can also slow recovery after surgery and raise the odds of cataract formation. Pharmacists and doctors keep a close eye on people’s progress, regularly checking eye pressure at appointments. Anyone noticing changes in vision, more eye pain, or new redness should call their provider instead of waiting for the next visit.
People sometimes stretch out a prescription, saving drops for future flare-ups. This causes trouble because old drops lose their punch and bacteria may grow after a few weeks. If the doctor says two weeks, stop as scheduled—don’t try to fix the next problem before it starts.
Many people in my neighborhood relied on eye drops for chronic allergies, and a few ended up needing pressure checks and extra appointments after extended use on their own. Folks forget that not every red or itchy eye calls for steroids. Cold compresses, allergy medicine, or preservative-free artificial tears work for less serious irritation. Checking in with an eye professional makes sense, especially before reaching for a bottle leftover in the medicine cabinet.
The FDA warns against unapproved products sold online, and using drops meant for someone else can complicate an infection and even threaten sight. Proper disposal keeps neighbors and kids safe too.
Listening to medical advice, practicing good hygiene, and returning for follow-up appointments anchor safe use of fluorometholone. Each step reduces the risks and gives the best shot at clear, pain-free vision after treatment. These habits build trust between patients, doctors, and the local pharmacy—making success more likely every time someone reaches for an eye drop bottle.
Fluorometholone shows up in eye drops that treat redness, swelling, and irritation. Doctors turn to this corticosteroid when inflammation in the eye causes pain or vision trouble. This drug packs a punch against allergic reactions too. As someone who grew up with family members prone to eye problems, I saw its use quiet some pretty stubborn flare-ups. But kids and expectant mothers bring extra questions to the table.
Not every child handles steroids in the same way as an adult. Their bodies absorb medications at different rates, and their eyes can feel long-term effects from stronger drugs. Published studies highlight that while fluorometholone works to control swelling, prolonged use in children can raise eye pressure, upping the risk for glaucoma. Some research also hints at a higher chance for cataract development with steroids over time.
Doctors lean toward caution. The American Academy of Ophthalmology mentions that for children, the drop dose often gets cut to the lowest amount for the shortest stretch of days. Family stories show the same—my cousin, diagnosed with eye allergies before kindergarten, rarely got steroid drops, and only with her doctor’s close watch. Parents always played it safe, booking frequent follow-ups and flagging any headaches or trouble seeing clearly. This care works as a guardrail against the side effects you can’t see right away.
Without clear signals that fluorometholone offers a big safety margin for young users, most eye doctors hesitate before reaching for it first in kids. Non-steroidal drops usually get a try before anything else. Only in stubborn cases, and only after an eye specialist weighs the benefits and risks, do they go with fluorometholone—and even then, not for long stretches.
Pregnancy mixes hope and worry, and every medicine gets extra scrutiny. Drug safety agencies list fluorometholone as a “Category C” medication for pregnant women in many parts of the world. That means animal research showed some negative effects on unborn pups, but controlled, high-quality studies in pregnant people simply don’t exist. Humans rarely get enrolled in those trials for obvious reasons—it’s hard to justify risking a baby’s health in the name of research.
Doctors look for options with better safety records. The US Food and Drug Administration, along with major global health groups, suggests skipping corticosteroid eye drops like fluorometholone during pregnancy unless the benefit sharply outweighs any risk. There are rare moments—think severe eye allergies that lead to damage or severe pain—where using it might make sense. In everyday cases, milder remedies win out. I have talked with pharmacists who won’t fill steroid drop prescriptions unless the prescriber includes a note spelling out why nothing else suffices.
If a child or pregnant person faces a situation where fluorometholone gets brought up, talking with a specialist becomes vital. Ask about possible alternatives, like antihistamine or artificial tear drops, which avoid the steroid risks. Always stick to eye drop schedules, call back for odd vision changes, and line up all medications for review if needed—every extra safeguard counts.
More research and better patient guidance could change recommendations someday. For now, health teams go step by step, aiming to protect vision and health in the safest way we know.
Eye inflammation rarely sits idle. Redness, swelling, tearing — these symptoms can derail focus and comfort. Fluorometholone steps in as a steroid eye drop, targeting inflammation with real force. Allergies, irritation after eye surgery, or chronic conditions make this medication a familiar prescription for many folks struggling to keep their vision clear and pain-free.
Steroids fix problems fast. But like any shortcut, there’s a cost with regular use. I remember seeing older relatives hesitate before accepting another refill, worried about what might happen after months of steady drops. They had good reason for concern. Data from published medical studies often points to side effects like increased eye pressure. If that pressure lingers unchecked, glaucoma could creep in, causing permanent vision change.
A survey in the American Journal of Ophthalmology laid out a pattern: those using steroid drops like fluorometholone longer than a few weeks faced a higher likelihood of eye pressure increases. Doctors often catch those cases at follow-up visits, but some patients slip through without realizing what’s building up behind their eyes.
Ignoring risk doesn’t shrink it. I talk with people terrified of losing their eyesight to glaucoma — a silent process that, if caught late, can’t always be reversed. Regular checkups aren’t a nuisance in this case. They’re insurance against silent damage. An ophthalmologist will check eye pressure at each appointment, sometimes adjusting the dosing schedule or changing medications based on those numbers.
The risk isn’t limited to pressure increases. Cataracts, which cloud vision and make night driving tricky, also show up in the research, especially with long steroid use. I watched a good friend’s father struggle with this after years of trusting his drops to keep inflammation down. He swapped steroids for another treatment, but the damage was done, his vision quality never the same.
Some doctors mix steroid treatments with non-steroidal anti-inflammatories to reduce exposure. For folks like allergy sufferers needing seasonal relief, pulsing treatment in bursts rather than an ongoing routine makes a world of difference. Artificial tears or antihistamines sometimes step in for milder symptoms, helping avoid steroids altogether during good months.
The best way forward usually combines careful dosing, vigilance at follow-up visits, and honest conversation about changes in vision. Any sign of blurred vision, more headaches, or changes in eye color needs a prompt phone call, not a wait-and-see.
No two eyes respond exactly alike. Families carry risk factors, and other medications can push things in the wrong direction. Regular follow-up visits build a safety net. Staying informed about new symptoms or family history means spotting trouble early, not after damage sets in. Using the lowest effective dose for the shortest possible time forms the best base strategy, supported by real-world experience and years of research.
Long-term fluorometholone use brings risk, but smart strategies and honest conversations with a trusted eye doctor reduce that danger. Eyesight stays precious — and worth every ounce of vigilance.
| Names | |
| Preferred IUPAC name | (6α,11β)-11,17-Dihydroxy-6-fluoro-17-(2-hydroxyacetyl)-pregna-1,4-diene-3,20-dione |
| Other names |
Fluorometolone
Fluorometholonum FML |
| Pronunciation | /fluːˌrōˌmiːˈθoʊlən/ |
| Preferred IUPAC name | (6α,11β)-11,17-Dihydroxy-6-methylpregna-1,4-diene-3,20-dione |
| Other names |
Fluorometolone
Fluormetolone Fluorometholon Fluorometholona FML |
| Pronunciation | /fluːˌrōˌmiːˈθəloʊn/ |
| Identifiers | |
| CAS Number | 426-13-1 |
| Beilstein Reference | 89679 |
| ChEBI | CHEBI:5104 |
| ChEMBL | CHEMBL1205 |
| ChemSpider | 72310 |
| DrugBank | DB00680 |
| ECHA InfoCard | 100.021.006 |
| EC Number | EC 4.2.1.11 |
| Gmelin Reference | 1071823 |
| KEGG | C07051 |
| MeSH | D005474 |
| PubChem CID | 33392 |
| RTECS number | DO7900000 |
| UNII | BQJZAPGBGJIS |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID9038987 |
| CAS Number | 426-13-1 |
| Beilstein Reference | 1842302 |
| ChEBI | CHEBI:5104 |
| ChEMBL | CHEMBL1533 |
| ChemSpider | 2341 |
| DrugBank | DB00324 |
| ECHA InfoCard | 100.010.346 |
| EC Number | EC 2.3.1.220 |
| Gmelin Reference | 78532 |
| KEGG | C07029 |
| MeSH | D005473 |
| PubChem CID | 3361 |
| RTECS number | VQ8750000 |
| UNII | 9U8T8G6J16 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID5015396 |
| Properties | |
| Chemical formula | C22H29FO4 |
| Molar mass | 376.463 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 0.994 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.99 |
| Vapor pressure | 4.62E-8 mmHg at 25°C |
| Acidity (pKa) | 12.71 |
| Basicity (pKb) | 4.74 |
| Magnetic susceptibility (χ) | -63.0e-6 cm^3/mol |
| Refractive index (nD) | 1.488 |
| Viscosity | Viscous liquid |
| Dipole moment | 1.78 D |
| Chemical formula | C22H29FO4 |
| Molar mass | 376.47 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 0.993 g/cm³ |
| Solubility in water | Insoluble |
| log P | 2.56 |
| Vapor pressure | 1.2 × 10⁻⁴ mmHg (25 °C) |
| Acidity (pKa) | 12.56 |
| Basicity (pKb) | 2.56 |
| Magnetic susceptibility (χ) | -98.6×10^-6 cm³/mol |
| Refractive index (nD) | 1.507 |
| Viscosity | 38 - 50 cP |
| Dipole moment | 1.73 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Fluorometholone is 484 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Fluorometholone is 485.9 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1091.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6152 kJ/mol |
| Pharmacology | |
| ATC code | S01BA05 |
| ATC code | S01BA05 |
| Hazards | |
| Main hazards | May cause eye irritation, temporary blurred vision, increased intraocular pressure, risk of infection, and allergic reactions |
| GHS labelling | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H319: Causes serious eye irritation. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | Fluorometholone: "1-1-0 |
| Lethal dose or concentration | LD50 (oral, rat): > 3 g/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 = 2392 mg/kg |
| NIOSH | DN6475000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.1 mg/m³ |
| IDLH (Immediate danger) | Not listed |
| Main hazards | May cause eye irritation. Prolonged use may result in glaucoma, cataract formation, or suppression of host response. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS06,GHS08 |
| Signal word | No signal word |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P210, P264, P273, P301+P312, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Autoignition temperature | 430 °C |
| Lethal dose or concentration | LD50 (rat, oral): > 4,000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50: >1,000 mg/kg |
| NIOSH | MF8140000 |
| PEL (Permissible) | PEL not established |
| REL (Recommended) | 0.05 mg/m³ |
| IDLH (Immediate danger) | Not Listed |
| Related compounds | |
| Related compounds |
Medrysone
Dexamethasone Prednisolone Triamcinolone Hydrocortisone |
| Related compounds |
Fluorometholone acetate
Betamethasone Dexamethasone Prednisolone Triamcinolone |
Providing high-quality chemical products and logistics solutions for global trade partners.
